eCQM Data Element Repository

October 2023
Objectives

• Learn how the Electronic Clinical Quality Measure (eCQM) Data Element Repository helps with eCQM data mapping activities.

• Learn how a health care organization uses the Data Element Repository to understand eCQM requirements.

• Describe resources available to learn more about CMS programs that use eCQMs.
eCQM Strategy Project Background
eCQM Strategy Project Background

eCQM Strategy Project Goals
• Reduce Burden
• Increase Value
• Increase Stakeholder Involvement

Problem Statement
• Providers participating in CMS quality and value-based purchasing programs have shared challenges they experience related to the complexity and high burden of eCQM implementation, data capture, and reporting.

Project Scope
• Measure Development process from concept to the Measures Under Consideration (MUC) list
• Electronic Clinical Quality Reporting requirements and processes from eCQM implementation to submission
• Tools for Development and Reporting
eCQM Strategy Recommendations

- eCQM reporting requirements across CMS program care settings
- eCQM specifications, value sets, and data collection

COMMUNICATION, EDUCATION, AND OUTREACH
- Coordinated education and outreach campaigns to learn from stakeholders and share CMS program information
- Measure-level webinars
- Clear eCQM guidance, plain language, and improved website usability

EHR CERTIFICATION PROCESS
- eCQM certification aligned with CMS reporting requirements

ALIGNMENT
- eCQM Strategy Goals: Reduce Burden, Increase Value, Increase Stakeholder Involvement

VALUE
- Quality dashboard best practice collaboration between providers and CMS
- Data element definitions

DEVELOPMENT PROCESS
- Measure Collaboration Workspace
- Data element repository
- Clinically feasible workflow for data capture
- Feasibility testing for new data elements

IMPLEMENTATION AND REPORTING PROCESSES
- Clear eCQM specifications, tools, and resources
- Feasible data elements
- Submission of data elements and eCQMs with FHIR and APIs
- Use of eCQM standards to support interoperability
- Consolidated pre-submission validation testing tools
- eCQM attribution research and pilots
Measure Collaboration Workspace
Measure Collaboration (MC) Workspace

- Hosted on the eCQI Resource Center (https://ecqi.healthit.gov/mc-workspace-2)
- Contains a set of interconnected resources, tools, and processes for eCQMs
- Promotes transparency and better interaction across stakeholder communities interested in developing and implementing more harmonized, accurate, and meaningful eCQMs
- Provides access to the eCQM Data Element Repository, an online, searchable tool that provides all the data elements associated with eCQMs used in CMS Quality Reporting Programs
How to Access the MC Workspace
Overview of the MC Workspace

- Suggest new eCQM concepts
- Offer comments on suggested eCQM concepts
- Check the CMS Measures Inventory for similar measures

Find eCQM data elements
Associate eCQM data elements with eCQMs
Find links to value sets and direct reference codes

Announce opportunities to test eCQMs
Find opportunities to volunteer to test eCQMs

https://ecqi.healthit.gov/mc-workspace-2
eCQM Data Element Repository
eCQM Data Element Repository Example Search


- Navigate to the eCQM Data Element Repository landing page and available filters
- Filter for 2024 EH/CAH eCQMs*
- Select CMS71v13 and highlight information available on measure pages with expand and collapse features to display data elements
- Identify value sets and direct reference codes in VSAC
- Identify eCQI Resource Center measure pages
- From Data Element Repository landing page, demonstrate information available on QDM filters

*EH/CAH = Eligible Hospital/Critical Access Hospital
Anticoagulation Therapy for Atrial Fibrillation/Flutter (STK-3)

CMS Measure ID: CMS71v13

Performance/Reporting Period: 2024

NQF Number: Not Applicable

Description:
Ischemic stroke patients with atrial fibrillation/flutter who are prescribed or continuing to take anticoagulation therapy at hospital discharge

Data Elements and coded QDM Attributes contained within the eCQM

["Assessment, Performed": "History of Atrial Ablation"]
["Diagnoses": "Atrial Fibrillation Or Flutter"]
["Diagnoses": "Hemorrhagic Stroke"]
["Diagnoses": "Ischemic Stroke"] [2.16.840.1.113883.3.117.1.71.1247]

https://ecqi.healthit.gov/measure-data-elements/179371
Anticoagulation Therapy for Atrial Fibrillation/Flutter (STK-3)
CMS Measure ID: CMS71v13 (Cont’d)

["Assessment, Performed": "History of Atrial Ablation"]

Performance/Reporting Period: 2024
Value Set Description from VSAC

CLINICAL FOCUS: The purpose of this value set is to represent concepts for a situation of a personal history of an atrial ablation.

DATA ELEMENT SCOPE: This value set may use a model element related to a diagnosis or assessment.

INCLUSION CRITERIA: Includes concepts that identify a situation for a personal history of an atrial ablation.

EXCLUSION CRITERIA: No Exclusions.

Constrained to codes in the History of Atrial Ablation value set (2.16.840.1.113762.1.4.1110.76).

QDM Datatype and Definition

"Assessment, Performed"

Data elements that meet criteria using this datatype should document completion of the assessment indicated by the QDM category and its corresponding value set.

Timing:

- relevant dateTime references timing for an assessment that occurs at a single point in time.
- relevant Period references a start and stop time for an assessment that occurs over a time interval
- author dateTime references the time the action was recorded.
- Refer to the eQM expression to determine allowable timings to meet measure criterion.


October 2023
Andrew Hamilton, MS, BSN, RN MS Chief Informatics Officer, AllianceChicago
Eduardo Segovia, BS, Manager, Data Warehouse Business Analyst, AllianceChicago
Tina Aggarwal, MS, BSN, RN, Clinical Informaticist, AllianceChicago

Health System Experience Using the eCQM Data Element Repository
Data Element Repository

Implementer Experience

Andrew Hamilton, RN, BSN, MS Chief Informatics Officer
Eduardo Segovia, BS Manager, Data Warehouse Business Analyst
Tina Aggarwal, MS, BSN, RN Clinical Informaticist

AllianceChicago
Innovating for better health
AllianceChicago – Who We Are

Our Mission
To improve personal, community and public health through innovative collaboration.

AllianceChicago’s efforts are focused in three core areas:

- Health Care Collaboration
- Health Information Technology
- Health Research + Education

User Community
60 community health centers from 18 states
AllianceChicago now has initiatives that span 18 States and engage more than:

- 60 Safety-net Health Centers
- >3,200,000 patients
- >20 Funders
- >20 Research Affiliations
AllianceChicago Data Warehouse Overview

HEALTH CATALYST

- athenaOne
- Intergy
- Centricity
- Epic
- Claims Data
- Other Clinical Data
- Social Determinant related data
- Other data sources
Prior Experience

- Universal HIV Screening Measure (CDC)
- Hepatitis C Screening (CDC)
- Contraceptive Measure (OPA)
- Heart Failure Measure Stratified by Race (NMQF)
Overview of Measure Implementation

- Obtain measure specification
- Feasibility analysis
- Assessing Chart Workflow
  - Mapping to local data
  - Localize to represent value sets
  - Develop logic for computing measure
  - Run measure testing and validation
  - Chart review to make sure accurate
- Program roll-out
CMS347v3: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease

Our process of building the eCQM for Statin Therapy.

How we implement the measure within organizations and measure testing.
Measure Description

- Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period:

- *Adults aged >= 21 years who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD); OR

- *Adults aged >= 21 years who have ever had a fasting or direct low-density lipoprotein cholesterol (LDL-C) level >= 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial or pure hypercholesterolemia; OR

- *Adults aged 40-75 years with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189 mg/dL

Performance Measures:

<table>
<thead>
<tr>
<th>Measure Name</th>
<th>Measure Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statin Therapy– ASCVD Risk Group</td>
<td>% of ASCVD patients age 21+ years who were prescribed or were on statin therapy during the measurement period</td>
</tr>
<tr>
<td>Statin Therapy – LDL-C level &gt;= 190 mg/dL Risk Group</td>
<td>% of patients age 21+ years with LDL-C level &gt;= 190 mg/dL who were prescribed or were on statin therapy during the measurement period</td>
</tr>
<tr>
<td>Statin Therapy – diabetes and LDL-C level 70-189 mg/dL Risk Group</td>
<td>% of patients age 40-75 years with diabetes and LDL-C level 70-189 mg/dL who were prescribed or were on statin therapy during the measurement period</td>
</tr>
<tr>
<td>Statin Therapy Cohort - Follow-up Visit</td>
<td>Number of patients at identified as high risk of cardiovascular events (all risk groups combined) who were NOT on statin therapy at baseline who return for 1 or more follow-up visits</td>
</tr>
<tr>
<td>Statin Therapy Cohort - Newly Prescribed Statin Therapy</td>
<td>Number of patients at identified as high risk of cardiovascular events (all risk groups combined) who were NOT prescribed or were on statin therapy at baseline who return for 1 or more follow-up visits AND who receive a subsequent prescription for statin therapy</td>
</tr>
</tbody>
</table>
Measure Specification

Statin Therapy for the Prevention and Treatment of Cardiovascular Disease

CMS Measure ID:
CMS347v3
Version:
3
NQF Number:
0
Performance/Reporting Period
2020

Description:
Percentage of the following patients – all considered at high risk of cardiovascular events – who were prescribed or were on statin therapy during the measurement period:

*Adults aged >= 21 years who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD); OR

*Adults aged >= 21 years who have ever had a fasting or direct low-density lipoprotein cholesterol (LDL-C) level >= 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial or pure hypercholesterolemia; OR

*Adults aged 40-75 years with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189 mg/dL

Data Elements contained within the eCQM

+ Expand all

Adverse Event: Statin Allergy
Allergy, Intolerance: Statin Allergen
Diagnosis: Atherosclerosis and Peripheral Arterial Disease
Diagnosis: Breastfeeding
Diagnosis: Cerebrovascular disease, Stroke, TIA
# Feasibility

- Feasibility scorecard (ex: HCV)

## Measure Title: HCV Learning Collaborative Feasibility Scorecard

<table>
<thead>
<tr>
<th>Measure</th>
<th>Data Element Attributes</th>
<th>Value Set Code Type</th>
<th>Timeline</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1945-1965 Birth Cohort</td>
<td>Administrative Code</td>
<td>Administrative Code</td>
</tr>
<tr>
<td>2</td>
<td>UDS Visit</td>
<td>Administrative Code</td>
<td>ID100M, ID100M, SNOMEDCT, COD, CPT, HCPCS, RXNORM</td>
</tr>
<tr>
<td>3</td>
<td>HCV risk factor - Current or past injection drug use</td>
<td>ID</td>
<td>TBD</td>
</tr>
<tr>
<td>4</td>
<td>HCV risk factor - History of IDU</td>
<td>ID</td>
<td>TBD</td>
</tr>
<tr>
<td>5</td>
<td>HCV risk factor - History of incarceration</td>
<td>ID</td>
<td>TBD</td>
</tr>
<tr>
<td>6</td>
<td>HCV Antibody</td>
<td>18.8401.1.132762.2.4.1056.72</td>
<td>CPT Code</td>
</tr>
<tr>
<td>7</td>
<td>Tested for HCV RNA</td>
<td>18.8401.1.132762.2.4.1056.73</td>
<td>CPT Code, LOINC</td>
</tr>
<tr>
<td>8</td>
<td>HCV Diagnosis</td>
<td></td>
<td>ICD</td>
</tr>
<tr>
<td>9</td>
<td>Linkage to HCV Care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>HCV Treatment Initiation</td>
<td></td>
<td>RxNorm Codes</td>
</tr>
<tr>
<td>11</td>
<td>HCV Care</td>
<td>18.8401.1.132762.2.4.1056.73</td>
<td>LOINC</td>
</tr>
</tbody>
</table>

### Notes
- **DATA AVAILABILITY**: Is the data readily available in a structured format?
- **DATA ACCURACY**: Is the information contained in the data element correct? Are the data source and recorder specified?
- **DATA STANDARDS**: Are the data elements coded using a national accepted terminology standard?
- **WORKFLOW**: To what degree is the data element captured during the course of care? How does it impact the typical workflow for managing the patient?
Assess Chart Workflow
Value Set Authority Center (VSAC)
# Mapping to Local Data

<table>
<thead>
<tr>
<th>Variable name</th>
<th>Variable description</th>
<th>Data type</th>
<th>Date specification</th>
<th>Centrivity table</th>
<th>Centrivity column</th>
<th>Centrivity value</th>
<th>HDID for OSS</th>
<th>Data value</th>
<th>Questions/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>PatientID</td>
<td></td>
<td>Numeric</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HealthCenterID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td>0 Main Categories</td>
<td></td>
<td></td>
<td>PatientProfile</td>
<td>PatientID</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethnicity</td>
<td>Hispanic/Latino, Not Hispanic/Latino</td>
<td></td>
<td></td>
<td>PatientProfile</td>
<td>HealthCenterID</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>Male, Female, Unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insurance Status</td>
<td>Insured, Uninsured, Patient's Primary Insurance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>as of 1/31/2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age Category</td>
<td>as of 1/31/2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Language</td>
<td>Best Served in a Language Other Than English. UDS Definition</td>
<td>Y/N</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDL Name</td>
<td>Recorded as the highest fasting or direct laboratory test result in the measurement year or during the two years prior to the beginning of the measurement period</td>
<td>Highest value between 2/1/2016-1/31/2019</td>
<td>obs</td>
<td>obsName</td>
<td>LDL 30</td>
<td>LDL (CALCUL)</td>
<td>LDL</td>
<td>LDL 30</td>
<td></td>
</tr>
</tbody>
</table>
Building Logic
# Measuring Testing/Validation

<table>
<thead>
<tr>
<th>PID</th>
<th>ETHNICITY</th>
<th>Sex</th>
<th>Age Category</th>
<th>ASOHCVCode</th>
<th>ASOHCVOnsetDate</th>
<th>LDLEver</th>
<th>LDL3YR</th>
<th>LDLMostRecent</th>
<th>Statin</th>
<th>DiabetesCode</th>
<th>DiabetesOrHyperchole</th>
<th>Hypercholesterolem</th>
<th>RiskGroup1_NUM</th>
<th>RiskGroup1</th>
<th>RiskG1</th>
</tr>
</thead>
<tbody>
<tr>
<td>635956517966</td>
<td>Not Hispanic F</td>
<td>28</td>
<td>Ages      25-54</td>
<td>G45.9</td>
<td>1/5/2015 0:00</td>
<td>86</td>
<td>86</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>735052337882</td>
<td>Hispanic M</td>
<td>40</td>
<td>Ages      35-44</td>
<td>G45.9</td>
<td>2/21/2017 0:00</td>
<td>179</td>
<td>179</td>
<td></td>
<td>179 ATORVASTATIN CALCIUM 40 MG ORAL TABLET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>73825666104</td>
<td>Hispanic M</td>
<td>62</td>
<td>Ages      55-64</td>
<td>G45.9</td>
<td>9/11/2014 0:00</td>
<td>119</td>
<td>110</td>
<td></td>
<td>110 ATORVASTATIN CALCIUM 40 MG ORAL TABLET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>74258047318</td>
<td>Not Hispanic M</td>
<td>63</td>
<td>Ages      55-64</td>
<td>G45.9</td>
<td>9/12/2019 0:00</td>
<td>186</td>
<td>186</td>
<td></td>
<td>186 LIPI TOR 20 MG ORAL TABLET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>74374622252</td>
<td>Unspecified F</td>
<td>46</td>
<td>Ages      45-54</td>
<td>G45.9</td>
<td>5/5/2019 0:00</td>
<td>86</td>
<td>86</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>62927487383</td>
<td>Not Hispanic F</td>
<td>37</td>
<td>Ages      35-44</td>
<td>G45.9</td>
<td>6/8/2019 0:00</td>
<td>114</td>
<td>103</td>
<td></td>
<td>103 ATORVASTATIN CALCIUM 20 MG ORAL TABLET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>62912668978</td>
<td>Not Hispanic F</td>
<td>57</td>
<td>Ages      55-64</td>
<td>G45.9</td>
<td>10/13/2014 0:00</td>
<td>116</td>
<td>87</td>
<td></td>
<td>87 ATORVASTATIN CALCIUM 40 MG ORAL TABLET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>62769000473</td>
<td>Not Hispanic F</td>
<td>46</td>
<td>Ages      45-54</td>
<td>G45.9</td>
<td>9/11/2015 0:00</td>
<td>175</td>
<td>165</td>
<td></td>
<td>165 ATORVASTATIN CALCIUM 40 MG ORAL TABLET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>732998831166</td>
<td>Not Hispanic M</td>
<td>46</td>
<td>Ages      45-54</td>
<td>G45.9</td>
<td>8/26/2019 0:00</td>
<td>144</td>
<td>69</td>
<td></td>
<td>69 ATORVASTATIN CALCIUM 40 MG ORAL TABLET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>753020586718</td>
<td>Not Hispanic F</td>
<td>46</td>
<td>Ages      45-54</td>
<td>G45.9</td>
<td>3/22/2016 0:00</td>
<td>216</td>
<td>186</td>
<td></td>
<td>186 SIMVASTATIN 40 MG ORAL TABLET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>753893888492</td>
<td>Not Hispanic F</td>
<td>46</td>
<td>Ages      45-54</td>
<td>G45.9</td>
<td>3/8/2016 0:00</td>
<td>58</td>
<td>58</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75611750464</td>
<td>Not Hispanic M</td>
<td>66</td>
<td>Ages      65-74</td>
<td>G45.9</td>
<td>1/5/2013 0:00</td>
<td>149</td>
<td>149</td>
<td></td>
<td>149 ATORVASTATIN CALCIUM 20MG TABLET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>759827012912</td>
<td>Not Hispanic F</td>
<td>46</td>
<td>Ages      45-54</td>
<td>G45.9</td>
<td>5/27/2015 0:00</td>
<td>128</td>
<td>110</td>
<td></td>
<td>110 ATORVASTATIN CALCIUM 20 MG ORAL TABLET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>758964872926</td>
<td>Not Hispanic M</td>
<td>50</td>
<td>Ages      45-54</td>
<td>G45.9</td>
<td>8/26/2017 0:00</td>
<td>120</td>
<td>120</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>757900542860</td>
<td>Not Hispanic M</td>
<td>57</td>
<td>Ages      55-64</td>
<td>G45.9</td>
<td>2/23/2017 0:00</td>
<td>137</td>
<td>137</td>
<td></td>
<td>137 SIMVASTATIN 40 MG ORAL TABLET</td>
<td></td>
<td></td>
<td>E11.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>757919652594</td>
<td>Not Hispanic M</td>
<td>51</td>
<td>Ages      45-54</td>
<td>G45.9</td>
<td>3/1/2018 0:00</td>
<td>177</td>
<td>69</td>
<td></td>
<td>69 ATORVASTATIN CALCIUM 80 MG ORAL TABLET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>758265557444</td>
<td>Not Hispanic M</td>
<td>65</td>
<td>Ages      65-74</td>
<td>G45.9</td>
<td>9/27/2019 0:00</td>
<td>65</td>
<td>62</td>
<td></td>
<td>62 LI PI TOR 10 MG ORAL TABLET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>74008817080</td>
<td>Not Hispanic F</td>
<td>49</td>
<td>Ages      45-54</td>
<td>G45.9</td>
<td>6/26/2019 0:00</td>
<td>152</td>
<td>102</td>
<td></td>
<td>102 LAVORSTATIN 20 MG ORAL TABLET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>741511608040</td>
<td>Not Hispanic F</td>
<td>52</td>
<td>Ages      45-54</td>
<td>G45.9</td>
<td>8/31/2017 0:00</td>
<td>90</td>
<td>80</td>
<td></td>
<td>80 ATORVASTATIN CALCIUM 10 MG ORAL TAI E11.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>741756277598</td>
<td>Not Hispanic F</td>
<td>59</td>
<td>Ages      55-64</td>
<td>G45.9</td>
<td>7/24/2018 0:00</td>
<td>122</td>
<td>122</td>
<td></td>
<td>122 ATORVASTATIN 40MG TABLETS</td>
<td></td>
<td></td>
<td>E11.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>742342422374</td>
<td>Not Hispanic M</td>
<td>51</td>
<td>Ages      45-54</td>
<td>G45.9</td>
<td>10/26/2018 0:00</td>
<td>118</td>
<td>115</td>
<td></td>
<td>115 ATORVASTATIN CALCIUM 10 MG ORAL TABLET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>743026885510</td>
<td>Not Hispanic M</td>
<td>55</td>
<td>Ages      55-64</td>
<td>G45.9</td>
<td>10/15/2018 0:00</td>
<td>108</td>
<td>78</td>
<td></td>
<td>78 ATORVASTATIN CALCIUM 40 MG ORAL TAI E11.65</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>740869113290</td>
<td>Not Hispanic F</td>
<td>55</td>
<td>Ages      55-64</td>
<td>G45.9</td>
<td>2/2/2018 0:00</td>
<td>145</td>
<td>124</td>
<td></td>
<td>124 ATORVASTATIN CALCIUM 20 MG ORAL TABLET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>741110936168</td>
<td>Not Hispanic F</td>
<td>52</td>
<td>Ages      45-54</td>
<td>G45.9</td>
<td>8/29/2019 0:00</td>
<td>106</td>
<td>106</td>
<td></td>
<td>106 ATORVASTATIN CALCIUM 80 MG ORAL TABLET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Chart Review - Denominator

• Data element | Diagnosis: Cerebrovascular disease, Stroke, TIA

**Value Set Description from VSAC**

**CLINICAL FOCUS:** This value set contains concepts that represent stroke and high risk diagnoses associated with stroke, including transient ischemic attack (TIA) and generalized ischemic cerebrovascular disease, which would indicate a patient has atherosclerotic cardiovascular disease (ASCVD) in relation to a cerebrovascular event.

**DATA ELEMENT SCOPE:** This value set may use the Quality Data Model (QDM) category or attribute related to Diagnosis.

**INCLUSION CRITERIA:** Includes only relevant concepts associated with ASCVD diagnoses of cerebrovascular origin.

**EXCLUSION CRITERIA:** No exclusions.

Constrained to codes in the Diagnosis: Cerebrovascular disease. Stroke. TIA value set (2.16.840.1.113762.1.4.1047.44).

<table>
<thead>
<tr>
<th>Description</th>
<th>ICD-9</th>
<th>ICD-10</th>
<th>Onset Date</th>
<th>End</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transient ischemic attack</td>
<td>435.9</td>
<td>G45.9</td>
<td>03-Jan-2020</td>
<td></td>
</tr>
<tr>
<td>Stroke</td>
<td>434.91</td>
<td>I63.9</td>
<td>10-Mar-2020</td>
<td></td>
</tr>
</tbody>
</table>
Chart Review- Numerator

• Data element | Medication, Order: Low intensity statin therapy

Value Set Description from VSAC

CLINICAL FOCUS: This value set contains concepts that represent low intensity statin medications as defined by the 2013 American College of Cardiology (ACC) and the American Heart Association (AHA) guideline.

DATA ELEMENT SCOPE: This value set may use the Quality Data Model (QDM) category related to Medication.

INCLUSION CRITERIA: Includes only relevant concepts associated with low intensity statin therapy medications.

EXCLUSION CRITERIA: Excludes any other intensity of statin therapy.

Constrained to codes in the Medication, Order: Low intensity statin therapy value set (2.16.840.1.113762.1.4.1047.107)
## Aggregate Report

**Statin Therapy - All Risk Groups**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Count</td>
<td>5954</td>
<td>5978</td>
<td>5975</td>
<td>5709</td>
<td>5936</td>
<td>6085</td>
<td>6201</td>
<td>6247</td>
<td>6355</td>
<td>6415</td>
<td>6436</td>
<td>6311</td>
<td>6058</td>
<td>6715</td>
<td>6640</td>
<td>6054</td>
<td>8451</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

**Number of patients ages 21+ years with 1+ visits in the past 12 months who met the above risk group criteria**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Count</td>
<td>11366</td>
<td>11439</td>
<td>11472</td>
<td>11353</td>
<td>11688</td>
<td>11763</td>
<td>11863</td>
<td>11956</td>
<td>12156</td>
<td>12333</td>
<td>12401</td>
<td>12604</td>
<td>12798</td>
<td>12915</td>
<td>13005</td>
<td>12967</td>
<td>12807</td>
<td>12751</td>
<td>0</td>
</tr>
</tbody>
</table>

**Statin Therapy - Diagnosis of ASCVD**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Count</td>
<td>231</td>
<td>259</td>
<td>250</td>
<td>263</td>
<td>268</td>
<td>275</td>
<td>282</td>
<td>281</td>
<td>280</td>
<td>291</td>
<td>288</td>
<td>324</td>
<td>348</td>
<td>355</td>
<td>356</td>
<td>357</td>
<td>355</td>
<td>366</td>
<td></td>
</tr>
</tbody>
</table>

**Number of patients ages 21+ years with 1+ visits in the past 12 months who met the following risk group criteria: Adults age 21+ years with a diagnosis of ASCVD**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Count</td>
<td>299</td>
<td>309</td>
<td>315</td>
<td>326</td>
<td>328</td>
<td>338</td>
<td>340</td>
<td>341</td>
<td>345</td>
<td>356</td>
<td>366</td>
<td>375</td>
<td>383</td>
<td>389</td>
<td>388</td>
<td>385</td>
<td>394</td>
<td>77.3%</td>
<td>77.3%</td>
</tr>
</tbody>
</table>

**Statin Therapy - LDL ≤130 mg/dL**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Count</td>
<td>1344</td>
<td>1383</td>
<td>1390</td>
<td>1275</td>
<td>1289</td>
<td>1282</td>
<td>1276</td>
<td>1261</td>
<td>1273</td>
<td>1269</td>
<td>1272</td>
<td>1243</td>
<td>1220</td>
<td>1210</td>
<td>1205</td>
<td>1198</td>
<td>1185</td>
<td>1179</td>
<td>1173</td>
</tr>
</tbody>
</table>

**Number of patients in denominator who are actively**

---

*All data is assumed and not actual.*
Program and Roll-Out

- Clinical committee buy-in
- Training on workflow
- Consideration of unintended consequences
- Wraparound support

Statin on Medication List: Ensure the patient’s statin medication is on the Medication List. Refer to the Disease Management Advisor for clinical decision support on statin prescribing, and the Alliance Statins Medication Custom List for easy access to prescribing recommended statins.
Engage and Get Help

• eCQI Resource Center and Contact Email
  o  https://ecqi.healthit.gov
  o  ecqi-resource-center@hhs.gov
• Share feedback on the Measure Collaboration Workspace
  o  https://ecqi.healthit.gov/contact
• Explore the CMS Measures Inventory Tool
  o  https://cmit.cms.gov/cmit/#/
• Engage with the eCQI community
  o  https://ecqi.healthit.gov/engage-ecqi
• Learn about eCQM communication resources
  o  https://ecqi.healthit.gov/sites/default/files/eCQMCommunicationResources.pdf
Additional Resources and Contact Information

• ONC Project Issue Tracking System (Jira)
  o https://oncprojecttracking.healthit.gov
• eCQI Community Engagement Opportunities
  o https://ecqi.healthit.gov/engage-ecqi